FOLINATO CÁLCICO NORMON 350 mg Polvo para solución inyectable EFG.

DRUG2 trials

Sponsors

Leap Therapeutics Inc., Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA

Conditions

Gastric AdenocarcinomaGastric cancerGastroEsophageal CancerLocalised Colon Cancer (stage II-III)

Phase 2

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)

CompletedCTIS2023-504940-32-00

Leap Therapeutics Inc.Gastric Adenocarcinoma, Gastric cancer, GastroEsophageal Cancer

Start: 2023-10-13End: 2025-02-17Target: 15Updated: 2024-09-26

Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA

Not yet recruitingCTIS2024-518131-11-02

Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVALocalised Colon Cancer (stage II-III)

Target: 124Updated: 2025-01-24